Literature DB >> 27209473

Surgical options for Chinese patients with early invasive breast cancer: Data from the Hong Kong Breast Cancer Registry.

Sharon W W Chan1, Catherine Cheung2, Amy Chan2, Polly S Y Cheung2.   

Abstract

BACKGROUND: Breast conserving surgery (BCS) is preferred for suitable candidates, while mastectomy (MTX) with reconstruction (MTX + R) is considered a better option for patients requiring MTX. In Hong Kong, the rates of BCS and breast reconstruction are relatively low. This paper aims to study the surgical options and their predictors among Hong Kong breast cancer patients.
METHODS: Data is retrieved from the Hong Kong Breast Cancer Registry (HKBCR) from 2007 to 2013. A total of 4519 Stage I-II breast cancer patients who had surgical treatments were included in this retrospective study.
RESULTS: Our multivariate logistic regression shows that people who were younger (age < 40 years: OR, 1.5; 95% CI, 1.1-2.1; p = 0.010), more educated (undergraduate/postgraduate: OR, 2.8; 95% CI, 1.7-4.4; p < 0.0001), never married (OR, 1.5; 95% CI, 1.1-1.9; p = 0.002), had regular mammography screening (OR, 1.5; 95% CI, 1.3-1.8; p < 0.0001), had screen-detected cancers (OR, 1.3; 95% CI, 1.0-1.6; p = 0.031), and who underwent surgery at a private medical service facility (OR, 1.8; 95% CI, 1.6-2.2; p < 0.0001) were more likely to receive BCS. In addition, people who were younger (age < 40 years: OR, 15.9; 95% CI, 6.5-39.2; p < 0.0001), more educated (undergraduate/postgraduate: OR, 26.8; 95% CI, 3.6-201.4; p = 0.001), had regular mammography screening (OR, 1.6; 95% CI, 1.1-2.3; p = 0.008), had screen-detected cancers (OR, 2.1; 95% CI, 1.4-3.3; p = 0.001), and had smaller tumor (≤ 2.0 cm: OR, 0.39; 95% CI, 0.20-0.76; p = 0.005) were more likely to have reconstruction after MTX.
CONCLUSION: Chinese patients have lower BCS and breast reconstruction rate. Besides cultural difference, patient-related factors such as age, education, marital status, mammography screening, the use of private medical facilities, and clinical characteristics including smaller tumor size and peripherally located tumor were significant predictors for type of surgical treatments in Chinese women with early breast cancer.
Copyright © 2016. Published by Elsevier Taiwan.

Entities:  

Keywords:  breast; breast conserving surgery; carcinoma; invasive ductal; mastectomy

Mesh:

Year:  2016        PMID: 27209473     DOI: 10.1016/j.asjsur.2016.02.003

Source DB:  PubMed          Journal:  Asian J Surg        ISSN: 1015-9584            Impact factor:   2.767


  5 in total

1.  Determinants of Breast-Conserving Therapy in the Asian Population: A Systematic Review.

Authors:  Maria Paz Galeano Machuca; Shelly Chien-Chien Cheng; Tony Hong-Ting Jou; Chih-Tao Cheng
Journal:  World J Surg       Date:  2020-10-13       Impact factor: 3.352

2.  Effect of patient decision aids on decisional conflict and regret associated with breast cancer surgery: a randomized controlled trial.

Authors:  Shi-Qian Lin; Chih-Ming Su; Hsueh-Chi Wu; Yun-Yun Chou; Yu-Chun Yen; Ka-Wai Tam
Journal:  Breast Cancer       Date:  2022-05-19       Impact factor: 3.307

3.  Post-operative radiotherapy is beneficial for T1/T2 triple negative breast cancer patients with four or more positive lymph nodes.

Authors:  Lin Chen; Jinfeng Zhang; Jiayi Chen; Lili Liu; Lili Liang; Zhiyi Shangguan; Dandan Wang
Journal:  Oncotarget       Date:  2017-06-27

4.  Reproductive risk factors associated with breast cancer in women in Bangui: a case-control study.

Authors:  Augustin Balekouzou; Ping Yin; Christian Maucler Pamatika; Cavin Epie Bekolo; Sylvain Wilfrid Nambei; Marceline Djeintote; Komlan Kota; Christian Diamont Mossoro-Kpinde; Chang Shu; Minghui Yin; Zhen Fu; Tingting Qing; Mingming Yan; Jianyuan Zhang; Shaojun Chen; Hongyu Li; Zhongyu Xu; Boniface Koffi
Journal:  BMC Womens Health       Date:  2017-03-06       Impact factor: 2.809

5.  Breast cancer mortality in Saudi Arabia: Modelling observed and unobserved factors.

Authors:  Refah Mohammed Alotaibi; Hoda Ragab Rezk; Consul Iworikumo Juliana; Chris Guure
Journal:  PLoS One       Date:  2018-10-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.